Thomas A. West - Feb 1, 2022 Form 4 Insider Report for Intersect ENT, Inc. (XENT)

Role
President and CEO, Director
Signature
/s/ Patrick A. Broderick, Attorney-in-Fact for Thomas A. West
Stock symbol
XENT
Transactions as of
Feb 1, 2022
Transactions value $
-$343,533
Form type
4
Date filed
2/4/2022, 08:05 PM
Previous filing
Dec 15, 2021
Next filing
May 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENT Common Stock Award $0 +107K +41.33% $0.00 364K Feb 1, 2022 Direct F1, F2
transaction XENT Common Stock Tax liability -$212K -7.76K -2.13% $27.31 357K Feb 2, 2022 Direct F3, F4, F5
transaction XENT Common Stock Tax liability -$132K -4.82K -1.35% $27.28 352K Feb 4, 2022 Direct F3, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the Vesting Commencement Date of February 1, 2022.
F2 Includes 500 shares purchased on 11/15/21 with ESPP plan and 281,359 restricted stock units, of which 39,700 are performance based.
F3 Shares tendered in payment of the tax withholding obligation in compliance and as required by the company's equity documents.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 to $27.55, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F5 Includes 260,526 restricted stock units, of which 39,700 are performance based.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.23 to $27.33, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F7 Includes 247,292 restricted stock units, of which 39,700 are performance based.